Shenwei Pharmaceutical (02877) announced that the profit attributable to the company's owners for the year ended December 31, 2023 is expected to increase by about 30% to 36% compared to the same period last year (2022: about RMB 723 million).
The expected increase in profit attributable to company owners this year is mainly due to an increase in the Group's overall sales revenue of about 14% compared to last year and a decrease of about 2 to 3 percent in the ratio of sales and distribution costs to turnover compared to last year.